Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Diabetes

Free Subscription Articles published in Circulation Retrieve available abstracts of 38 articles: HTML format

Single Articles

August 2026
1. DAI Y, Li Q, Ding F, Chen S, et al
   Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes.
   Circulation. 2026 Aug 25. doi: 10.1161/CIRCULATIONAHA.125.078171.
   PubMed     Abstract available
   
   
   July 2026
2. NAU C, Wu JHY, Han B, Habib M, et al
   Effects of a "Food Is Medicine" Intervention on Glucose Control Among Medicaid-Insured Patients With Type 2 Diabetes: A Randomized Controlled Trial.
   Circulation. 2026 Jul 21. doi: 10.1161/CIRCULATIONAHA.125.077982.
   PubMed     Abstract available
   
   
   
3. PIGEYRE M, Gerstein HC
   Cardiovascular Risk Reduction With GLP-1 RA Drugs.
   Circulation. 2026;154:66-73.
   PubMed     Abstract available
   
   
   April 2026
4. SUMIYOSHI T, Iijima K, Fujiki S, Hirabayashi K, et al
   Effect of Empagliflozin on Device-Measured Thoracic Impedance in Patients With Type 2 Diabetes Treated With an Implantable Cardioverter Defibrillator.
   Circulation. 2026;153:1343-1346.
   PubMed    
   
   
   
5. INOUE K, Kazi DS
   GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation?
   Circulation. 2026;153:1101-1103.
   PubMed    
   
   
   March 2026
6. GAO P, Li L, Zou Y
   Response by Gao et al to Letter Regarding Article, "G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice".
   Circulation. 2026;153:e1057.
   PubMed    
   
   
   
7. WU D, Zhang J, Yang J
   Letter by Wu et al Regarding Article, "G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice".
   Circulation. 2026;153:e1055-e1056.
   PubMed    
   
   
   
8. ZHANG Z, Zhu D, Liu C, Gan L, et al
   Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.
   Circulation. 2026 Mar 2. doi: 10.1161/CIRCULATIONAHA.125.076372.
   PubMed     Abstract available
   
   
   February 2026
9. XU Y, Huang T, Zhang Y, Ji D, et al
   Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
   Circulation. 2026 Feb 24. doi: 10.1161/CIRCULATIONAHA.125.075157.
   PubMed     Abstract available
   
   
   
10. HUNDERTMARK MJ, Birkhoelzer SM, Portwood C, Siu AG, et al
    IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
    Circulation. 2026;153:550-563.
    PubMed     Abstract available
    
    
    January 2026
11. XU J, Wu Y, Song P, Zhang M, et al
    Retraction of: Proteasome-Dependent Degradation of Guanosine 5'-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus.
    Circulation. 2026 Jan 30. doi: 10.1161/CIR.0000000000001420.
    PubMed    
    
    
    
12. ZHAO YT
    Letter by Zhao Regarding Article, "Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial".
    Circulation. 2026;153:e8-e9.
    PubMed    
    
    
    September 2025
13. SHI F, Zheng B, Liu Y
    Letter by Shi et al Regarding Article "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
    Circulation. 2025;152:e71-e72.
    PubMed    
    
    
    
14. SILBERNAGEL G, Wen Y, Konrad RJ
    Response by Silbernagel et al to Letters Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
    Circulation. 2025;152:e73-e74.
    PubMed    
    
    
    
15. HUANG J
    Letter by Huang Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
    Circulation. 2025;152:e69-e70.
    PubMed    
    
    
    August 2025
16. GAO P, Cao M, Wang X, Zhang H, et al
    G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.
    Circulation. 2025 Aug 7. doi: 10.1161/CIRCULATIONAHA.125.073947.
    PubMed     Abstract available
    
    
    May 2025
17. WANG C, Shen S, Kang J, Sugai-Munson A, et al
    METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
    Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.124.070279.
    PubMed     Abstract available
    
    
    
18. SATTAR N, Weerakkody GJ, McGuire DK, Kosiborod MN, et al
    The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
    Circulation. 2025;151:1430-1432.
    PubMed    
    
    
    April 2025
19. DONG J, Yang X, Zhang W
    Letter by Dong et al Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
    Circulation. 2025;151:e962-e963.
    PubMed    
    
    
    
20. BONNESEN K, Heide-Jorgensen U, Schmidt M
    Response by Bonnesen et al to Letter Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
    Circulation. 2025;151:e964.
    PubMed    
    
    
    March 2025
21. MARX N, Deanfield JE, Mann JFE, Arechavaleta R, et al
    Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
    Circulation. 2025 Mar 29. doi: 10.1161/CIRCULATIONAHA.125.074545.
    PubMed     Abstract available
    
    
    February 2025
22. YU AYX, Auger N, Fu L, Chu A, et al
    Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes.
    Circulation. 2025;151:508-510.
    PubMed    
    
    
    January 2025
23. 
    Correction to: Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2025;151:e30.
    PubMed    
    
    
    
24. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    PubMed    
    
    
    December 2024
25. BIRKENFELD AL, Franks PW, Mohan V
    Precision Medicine in People at Risk for Diabetes and Atherosclerotic Cardiovascular Disease: A Fresh Perspective on Prevention.
    Circulation. 2024;150:1910-1912.
    PubMed    
    
    
    October 2024
26. SILBERNAGEL G, Chen YQ, Li H, Lemen D, et al
    Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
    Circulation. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272.
    PubMed     Abstract available
    
    
    August 2024
27. NEUEN BL, Fletcher RA, Heath L, Perkovic A, et al
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071689.
    PubMed     Abstract available
    
    
    
28. BONNESEN K, Heide-Jorgensen U, Christensen DH, Lash TL, et al
    Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2024 Aug 29. doi: 10.1161/CIRCULATIONAHA.124.068613.
    PubMed     Abstract available
    
    
    
29. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    PubMed     Abstract available
    
    
    
30. RAJAGOPALAN S, Dobre M, Dazard JE, Vergara-Martel A, et al
    Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial.
    Circulation. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.123.067620.
    PubMed     Abstract available
    
    
    July 2024
31. NEUEN BL, Claggett BL, Perkovic V, Jardine M, et al
    Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials.
    Circulation. 2024;150:343-345.
    PubMed    
    
    
    June 2024
32. TANNU M, Kaltenbach L, Pagidipati NJ, McGuire DK, et al
    Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.
    Circulation. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.124.068962.
    PubMed     Abstract available
    
    
    April 2024
33. NEUEN BL, Tuttle KR, Vaduganathan M
    Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.
    Circulation. 2024;149:1238-1240.
    PubMed    
    
    
    
34. BLOOD AJ, Chang LS, Hassan S, Chasse J, et al
    Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494.
    PubMed     Abstract available
    
    
    
35. PATEL SM, Kang YM, Im K, Neuen BL, et al
    Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568.
    PubMed     Abstract available
    
    
    March 2024
36. BILLING AM, Kim YC, Gullaksen S, Schrage B, et al
    Metabolic Communication by SGLT2 Inhibition.
    Circulation. 2024;149:860-884.
    PubMed     Abstract available
    
    
    
37. GABA P, Sabik JF, Murphy SA, Bellavia A, et al
    Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
    Circulation. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571.
    PubMed     Abstract available
    
    
    December 2023
38. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum